A short review on antibody therapy for COVID-19

A short review on antibody therapy for COVID-19

The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychl...

Full description

Bibliographic Details
Main Authors: G. Venkat Kumar, V. Jeyanthi, S. Ramakrishnan
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:New Microbes and New Infections
Subjects:
Convalescent plasma therapy
monoclonal antibody therapy
receptor binding domain
SARS-CoV-2
spike protein
Online Access:http://www.sciencedirect.com/science/article/pii/S2052297520300342
Description
Summary:The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.
ISSN:2052-2975

Similar Items